Ocular Therapeutix Analyst Ratings
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $15
Buy Rating Affirmed for Ocular Therapeutix on Robust Revenue Growth and Clinical Trial Prospects
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)
TD Cowen Adjusts Price Target on Ocular Therapeutix to $11 From $8, Maintains Market Perform Rating
Ocular Therapeutix Analyst Ratings
Buy Rating Affirmed for Ocular Therapeutix on Strong Phase 3 Results and Strategic Focus
Balanced Outlook: Hold Rating on Ocular Therapeutix Amidst Trial Progress and Management Changes
Ocular Therapeutix Analyst Ratings
Strategic Leadership and Strong Financials Bolster Buy Rating for Ocular Therapeutix
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Edesa Biotech (EDSA) and Ocular Therapeutix (OCUL)
Ocular Therapeutix Analyst Ratings
Piper Sandler Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)
Ocular Therapeutix Analyst Ratings
Piper Sandler Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Ocular Therapeutix (OCUL)
Optimistic Buy Rating for Ocular Therapeutix as FDA Amends Axpaxli Phase 3 Trial Protocol
Piper Sandler Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Aclaris Therapeutics (ACRS) and Ocular Therapeutix (OCUL)
Analysts Offer Insights on Healthcare Companies: InMode (INMD), Ocular Therapeutix (OCUL) and Adverum Biotechnologies (ADVM)
No Data